D Bioprinting Market. The global 3D bioprinting market is projected to reach USD 2.24 billion by 2024, with demand expected ...

Designation underscores significant unmet need in frontotemporal dementia and the potential role of neflamapimod in multiple neurologic disorders On track to report topline data from the RewinD-LB ...

Japanese mid-size drugmaker Otsuka Pharmaceutical announced that it has entered into an exclusive worldwide licensing ...

Hormone therapy resistance and the ensuing aggressive tumor progression present a significant clinical challenge. However, the mechanisms underlying the induction of tumor malignancy upon inhibition ...

LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, and the Hamoui Foundation are proud to announce the recipients of the Hamoui Foundation/LUNGevity Clinical ...

Gastrointestinal stromal tumours (GISTs) are clinically heterogeneous, with varying degrees of aggressiveness. Here, the authors describe the genomic and transcriptomic landscape of 117 GISTs from ...

Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...

Adaptimmune Therapeutics is prepping for another FDA submission after 42% of patients with sarcoma responded to the company's investigational cell therapy in a pivotal phase 2 trial. The primary ...

Researchers have developed an AI-powered model that—in 10 seconds—can determine during surgery if any part of a cancerous brain tumor that could be removed remains, a study published in Nature ...

Whether it's Hershey’s Kisses, Reese's peanut butter bars or Kit Kats, the Hershey's brand is the most popular chocolate brand in the world. In Hershey, Pennsylvania, the history of cocoa-fused ...

Elraglusib is undergoing investigation in an open-label, multicenter, phase 1/2 trial for the treatment of patients with Ewing sarcoma. Elraglusib has been granted rare pediatric disease designation ...